Loading...
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
Gelderblom, H Blay, J Seddon, B Leahy, Michael G Ray-Coquard, I Sleijfer, S Kerst, J M Rutkowski, P Bauer, S Ouali, M
Gelderblom, H
Blay, J
Seddon, B
Leahy, Michael G
Ray-Coquard, I
Sleijfer, S
Kerst, J M
Rutkowski, P
Bauer, S
Ouali, M
Citations
Altmetric:
Abstract
Brostallicin is a DNA minor groove binder that has shown activity in patients with soft tissue sarcoma (STS) failing first-line therapy. The present study assessed the safety and efficacy of first-line brostallicin in patients with advanced or metastatic STS >60 years or not fit enough to receive combination chemotherapy. A prospective explorative pharmacogenetic analysis was undertaken in parallel.
Affiliation
Description
Date
2014-01
Publisher
Collections
Keywords
Type
Article
Citation
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. 2014, 50 (2):388-96 Eur J Cancer